ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1047
0,00%
Bitcoin
67.040,75
-0,06%
Brent Oil
83,76
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Viking Therapeutics Inc (VKTX)

  7. Viking Therapeutics Inc (VKTX) Notícias

VKTX

Viking Therapeutics (VKTX)

Viking Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:VKTX
DataHoraFonteTítuloCódigoCompanhia
24/04/202417:05PR Newswire (US)Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VKTXViking Therapeutics Inc
24/04/202408:31IH Market NewsU.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures TradingNASDAQ:VKTXViking Therapeutics Inc
17/04/202417:05PR Newswire (US)Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024NASDAQ:VKTXViking Therapeutics Inc
26/03/202408:03PR Newswire (US)Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735NASDAQ:VKTXViking Therapeutics Inc
04/03/202421:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
04/03/202418:52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
04/03/202418:45PR Newswire (US)Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:VKTXViking Therapeutics Inc
01/03/202418:13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VKTXViking Therapeutics Inc
28/02/202422:50PR Newswire (US)Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common StockNASDAQ:VKTXViking Therapeutics Inc
27/02/202418:19PR Newswire (US)Viking Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:VKTXViking Therapeutics Inc
27/02/202409:03PR Newswire (US)Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with ObesityNASDAQ:VKTXViking Therapeutics Inc
09/02/202418:01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
07/02/202419:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VKTXViking Therapeutics Inc
07/02/202419:24Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VKTXViking Therapeutics Inc
07/02/202418:05PR Newswire (US)Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateNASDAQ:VKTXViking Therapeutics Inc
31/01/202418:05PR Newswire (US)Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024NASDAQ:VKTXViking Therapeutics Inc
13/11/202318:02PR Newswire (US)Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023NASDAQ:VKTXViking Therapeutics Inc
02/11/202317:03PR Newswire (US)Viking Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:VKTXViking Therapeutics Inc
25/10/202318:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VKTXViking Therapeutics Inc
25/10/202317:05PR Newswire (US)Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VKTXViking Therapeutics Inc
23/10/202308:05PR Newswire (US)Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with ObesityNASDAQ:VKTXViking Therapeutics Inc
18/10/202317:05PR Newswire (US)Viking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023NASDAQ:VKTXViking Therapeutics Inc
18/10/202310:06IH Market NewsKeep An Eye Out: Pre-Market Movers And Analyst RecommendationsNASDAQ:VKTXViking Therapeutics Inc
18/10/202310:03IH Market NewsWednesday’s Wall Street Highlights: ASML, Nvidia, United Airlines, Viking Therapeutics, P&G, and MoreNASDAQ:VKTXViking Therapeutics Inc
17/10/202317:05PR Newswire (US)Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023NASDAQ:VKTXViking Therapeutics Inc
10/10/202317:05PR Newswire (US)Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023NASDAQ:VKTXViking Therapeutics Inc
06/09/202308:03PR Newswire (US)Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with ObesityNASDAQ:VKTXViking Therapeutics Inc
26/07/202318:26Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:VKTXViking Therapeutics Inc
26/07/202317:05PR Newswire (US)Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VKTXViking Therapeutics Inc
19/07/202317:05PR Newswire (US)Viking Therapeutics to Report Financial Results for Second Quarter 2023 on July 26, 2023NASDAQ:VKTXViking Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:VKTX

Seu Histórico Recente

COIN
KGCUSD
BIT
S28226
Societe Generale Effekten
COIN
OFUST
BIT
T00007
Banca Cesare Ponti
LSE
LGEN
Legal & General
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados